Mangalam Drugs [MANGALAM] vs Lotus Eye Hospital [LOTUSEYE] Detailed Stock Comparison

Mangalam Drugs and Organics Ltd.

NSE
Loading...

Lotus Eye Hospital and Institute Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 18 vital metrics comparison: Mangalam Drugs and Organics Ltd. wins in 10 metrics, Lotus Eye Hospital and Institute Ltd. wins in 7 metrics, with 0 ties. Mangalam Drugs and Organics Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Mangalam Drugs and Organics Ltd. Lotus Eye Hospital and Institute Ltd. Better
P/E Ratio (TTM) 19.47 371.78 Mangalam Drugs and Organics Ltd.
Price-to-Book Ratio 0.35 3.79 Mangalam Drugs and Organics Ltd.
Debt-to-Equity Ratio 79.54 7.92 Lotus Eye Hospital and Institute Ltd.
PEG Ratio -0.02 20.45 Lotus Eye Hospital and Institute Ltd.
EV/EBITDA 42.27 102.16 Mangalam Drugs and Organics Ltd.
Profit Margin (TTM) -13.01% 1.26% Lotus Eye Hospital and Institute Ltd.
Operating Margin (TTM) -10.09% -2.40% Lotus Eye Hospital and Institute Ltd.
Return on Equity 4.51% 1.23% Mangalam Drugs and Organics Ltd.
Return on Assets (TTM) 1.83% 1.06% Mangalam Drugs and Organics Ltd.
Free Cash Flow (TTM) $223.93M $-21.28M Mangalam Drugs and Organics Ltd.
1-Year Return -65.07% 87.80% Lotus Eye Hospital and Institute Ltd.
Price-to-Sales Ratio (TTM) 0.19 4.79 Mangalam Drugs and Organics Ltd.
Enterprise Value $1.43B $2.23B Lotus Eye Hospital and Institute Ltd.
EV/Revenue Ratio 0.60 4.31 Mangalam Drugs and Organics Ltd.
Gross Profit Margin (TTM) 36.49% N/A N/A
Revenue per Share (TTM) $150 $25 Mangalam Drugs and Organics Ltd.
Earnings per Share (Diluted) $-19.53 $0.32 Lotus Eye Hospital and Institute Ltd.
Beta (Stock Volatility) 0.10 0.57 Mangalam Drugs and Organics Ltd.

Mangalam Drugs and Organics Ltd. vs Lotus Eye Hospital and Institute Ltd. Stock Performance Analysis

Loading Price Chart...

MANGALAM
LOTUSEYE

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Mangalam Drugs and Organics Ltd.4.97%3.97%-1.24%-3.02%17.10%2.42%
Lotus Eye Hospital and Institute Ltd.3.61%18.71%31.36%30.60%6.44%16.21%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Mangalam Drugs and Organics Ltd.-65.07%-74.51%-80.83%-80.88%120.16%109.52%
Lotus Eye Hospital and Institute Ltd.87.80%65.97%207.74%690.06%1,106.25%278.96%

Performance & Financial Health Analysis: Mangalam Drugs and Organics Ltd. vs Lotus Eye Hospital and Institute Ltd.

MetricMANGALAMLOTUSEYE
Market Information
Market Cap i₹447.94M₹2.63B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i20,86718,128
90 Day Avg. Volume i39,77713,595
Last Close₹29.58₹139.98
52 Week Range₹22.80 - ₹95.00₹67.72 - ₹147.00
% from 52W High-68.86%-4.78%
All-Time High₹442.40 (Dec 07, 2015)₹147.00 (Jan 30, 2026)
% from All-Time High-93.31%-4.78%
Growth Metrics
Quarterly Revenue Growth-0.34%0.11%
Quarterly Earnings Growth-0.34%N/A
Financial Health
Profit Margin (TTM) i-0.13%0.01%
Operating Margin (TTM) i-0.10%-0.02%
Return on Equity (TTM) i0.05%0.01%
Debt to Equity (MRQ) i79.547.92
Cash & Liquidity
Book Value per Share (MRQ)₹80.58₹31.41
Cash per Share (MRQ)₹2.13₹1.62
Operating Cash Flow (TTM) i₹24.29M₹5.77M
Levered Free Cash Flow (TTM) i₹67.21M₹7.39M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend i₹0.00₹0.00

Valuation & Enterprise Metrics Analysis: Mangalam Drugs and Organics Ltd. vs Lotus Eye Hospital and Institute Ltd.

MetricMANGALAM (Apr 24, 2026)LOTUSEYE (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i19.47371.78
Forward P/E iN/AN/A
PEG Ratio i-0.0220.45
Price to Sales (TTM) i0.194.79
Price to Book (MRQ) i0.353.79
Market Capitalization
Market Capitalization i₹447.94M₹2.63B
Enterprise Value i₹1.43B₹2.23B
Enterprise Value Metrics
Enterprise to Revenue i0.604.31
Enterprise to EBITDA i42.27102.16
Risk & Other Metrics
Beta i0.100.57
Book Value per Share (MRQ) i₹80.58₹31.41

Financial Statements Comparison: Mangalam Drugs and Organics Ltd. vs Lotus Eye Hospital and Institute Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricMANGALAM (2025)LOTUSEYE (2025)
Revenue/Sales i3.15B486.03M
Cost of Goods Sold i1.92B259.50M
COGS % of Revenue i60.9%53.4%
Gross Profit i1.23B226.53M
Gross Margin i39.1%46.6%
Research & Development iN/AN/A
Operating Income (EBIT) i173.92M5.52M
Operating Margin i5.5%1.1%
EBITDA i324.99M47.35M
EBITDA Margin i10.3%9.7%
Pre-Tax Income i47.86M13.83M
Pre-Tax Income % of Revenue i1.5%2.8%
Income Tax i-19.35M6.43M
Income Tax % of Revenue i-0.6%1.3%
Net Income (Profit) i67.21M7.39M
Profit Margin i2.1%1.5%

Balance Sheet & Liquidity Metrics

MetricMANGALAM (2025)LOTUSEYE (2025)
Cash & Equivalents i25.89M20.11M
Total Current Assets i1.99B115.70M
Total Current Assets % of Revenue i63.1%23.8%
Total Current Liabilities i1.92B74.25M
Total Current Liabilities % of Revenue i60.8%15.3%
Long-Term Debt i117.49M20.27M
Long-Term Debt % of Revenue i3.7%4.2%
Total Shareholders Equity i1.49B600.00M
Retained Earnings i928.38M143.09M
Retained Earnings % of Revenue i29.5%29.4%
Property, Plant & Equipment i316.91M442.83M

Cash Flow Statement Comparison

MetricMANGALAM (2025)LOTUSEYE (2025)
Operating Cash Flow i24.29M5.77M
Operating Cash Flow % of Revenue i0.8%1.2%
Capital Expenditures i-194.73M-47.90M
Free Cash Flow i223.93M-21.28M
FCF Margin i7.1%-4.4%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricMANGALAMLOTUSEYE
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i15.83M20.80M
Float Shares i8.87M4.56M
% Held by Insiders i53.30%71.94%
% Held by Institutions i0.00%0.00%
% Held by Public i46.70%28.06%

Dividend Analysis & Yield Comparison: Mangalam Drugs and Organics Ltd. vs Lotus Eye Hospital and Institute Ltd.

MetricMANGALAMLOTUSEYE
Last 12-Month Dividend i₹0.00₹0.00
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend i₹0.00₹0.33
3-Year Avg Dividend Yield iN/A0.66%
3-Year Total Dividends i₹0.00₹1.00
Ex-Dividend DateN/ASep 18, 2023